Global Initiative

Fixed-Dose Combination of Albuterol and Budesonide (PT027) Demonstrated Significant Benefits for Asthma Patients in MANDALA and DENALI Phase III Trials

Retrieved on: 
Jeudi, septembre 9, 2021
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials

The trial included 3,132 patients with moderate to severe asthma taking maintenance ICS with or without additional controller medicines.

Key Points: 
  • The trial included 3,132 patients with moderate to severe asthma taking maintenance ICS with or without additional controller medicines.
  • Inflammation is a distinctive feature of asthma and plays a key role in asthma symptoms, exacerbations and deaths.
  • Many millions of patients globally rely on their rescue inhaler to alleviate acute symptoms, but this does not treat the underlying inflammation in asthma.
  • The MANDALA and DENALI trials demonstrate an albuterol/budesonide rescue inhaler can address inflammation and prevent exacerbations, making PT027 an important potential new treatment option for patients.

Pulmonx Announces Anthem Blue Cross Blue Shield Now Provides Coverage for Severe COPD/Emphysema Treatment

Retrieved on: 
Vendredi, août 20, 2021
Medical Devices, Insurance, Hospitals, Clinical Trials, Professional Services, Other Health, Biotechnology, Managed Care, General Health, Health, SEC, COPD, Securities Act of 1933, Safety, Endobronchial valve, Lung, Atmosphere, GOLD, Securities Exchange Act of 1934, University, U.S. Securities and Exchange Commission, Policy, Health Care Service Corporation, Â, Breathe Me, Blues, Degenerative disease, Respiratory disease, Quality of life, Drug Quality and Security Act, Adoption, BCBS, Valve, NASDAQ, Chronic obstructive pulmonary disease, FDA, Security (finance), Oxygen, Corporation, LVRS, Global Initiative, Interventional pulmonology, Bronchoscopy, Han Lifei (d. 1424), Patient, Medical imaging, the Zephyr Valve Treatment, Pulmonx Corporation, THE ZEPHYR VALVE TREATMENT, PULMONX CORPORATION

Pulmonx Corporation (Nasdaq: LUNG) (Pulmonx), a global leader in minimally invasive treatments for severe lung disease, today announced that Anthem Blue Cross Blue Shield (BCBS) has issued a positive coverage policy for endobronchial valves, including Pulmonxs Zephyr Valve, for severe emphysema, a form of COPD.

Key Points: 
  • Pulmonx Corporation (Nasdaq: LUNG) (Pulmonx), a global leader in minimally invasive treatments for severe lung disease, today announced that Anthem Blue Cross Blue Shield (BCBS) has issued a positive coverage policy for endobronchial valves, including Pulmonxs Zephyr Valve, for severe emphysema, a form of COPD.
  • This follows similar coverage decisions by other BCBS plans and brings the total BCBS covered members in the US to 59 million.
  • Not surprisingly, the policy cites our published data, which demonstrate the safety, effectiveness and long-term positive patient outcomes of our Zephyr valve treatment."
  • The Zephyr Valve is a minimally invasive treatment option for severe COPD/emphysema, a chronic, progressive, and irreversible lung disease characterized by the destruction of lung tissue.

 COVID-19 Sequencing is a Must to Curb Rampant Variants, says AHF

Retrieved on: 
Jeudi, août 12, 2021
Public Policy, Government, Health, Public Policy, Infectious Diseases, Genetics, General Health, Biotechnology, AIDS, AHF, University, COVID-19, Twitter, Instagram, GISAID, Coronavirus, Facebook, Leadership, AIDS Healthcare Foundation, Severe acute respiratory syndrome coronavirus 2, Knowledge, Global Initiative, Animal

With a reporting lag of over 2.5 months, data this old severely undermines efforts to respond to a constantly changing virus.

Key Points: 
  • With a reporting lag of over 2.5 months, data this old severely undermines efforts to respond to a constantly changing virus.
  • Without timely global genomic sequencing data, we are flying blind and fighting yesterdays war.
  • We are funding genomic sequencing projects as a way to show that we are not only talking about it and demanding more action, but also doing it.
  • To learn more about AHF, please visit our website: www.aidshealth.org , find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210812005698/en/

INNIO Joins United Nations Global Compact Further Underscoring Commitment to Sustainability

Retrieved on: 
Mardi, août 10, 2021
Other Energy, Utilities, Philanthropy, Oil, Gas, Nuclear, Coal, Alternative Energy, Energy, Environment, Other Policy Issues, Other Philanthropy, Public Policy, Government, Industry, SRB, CEO, United Nations Global Compact, UN, LinkedIn, Global Compact, Silver medal, Efficiency, Jenbacher, Electricity, Carbon, Technology, Yunus Social Business – Global Initiatives, Solution, ESG, Twitter, Goal, Environment, Natural gas, Hydrogen, Sustainable Development Goal 13, Multimedia, Disclosure, Global Initiative, Human, Sustainable Development Goals, Silver, Renewable energy, Management

INNIO today announced that it has joined the United Nations Global Compact , the worlds largest corporate sustainability initiative.

Key Points: 
  • INNIO today announced that it has joined the United Nations Global Compact , the worlds largest corporate sustainability initiative.
  • In joining this critical voluntary leadership platform, INNIO continues its path to build on an expanded commitment to its environmental, social and governance (ESG) program.
  • In an act to cement its commitment to sustainability, INNIO leadership in conjunction with its SRB moved swiftly to become a participant of the Global Compact.
  • Launched in 2000, the UN Global Compact is composed of more than 9,500 companies and 3,000 non-business signatories based in over 160 countries, and more than 70 Local Networks.